| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
45,000,000 |
| Market
Cap: |
186.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.2 - $8.52 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verastem is a late stage development biopharmaceutical company, with ongoing registration directed trials, focused on developing and commercializing medicines for patients battling cancer. Co.'s product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors. VS-6766 is an orally available small molecule rapidly accelerated fibrosarcoma/ mitogen-activated protein kinase kinase clamp. Defactinib is an oral small molecule inhibitor of Focal Adhesion Kinase and proline-rich tyrosine kinase that is being evaluated as a potential combination therapy for various solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,796 |
104,440 |
112,251 |
137,798 |
| Total Sell Value |
$693,034 |
$751,285 |
$775,014 |
$1,057,744 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
9 |
17 |
37 |
75 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Calkins Daniel |
Chief Financial Officer |
• – – |
2025-06-23 |
4 |
S |
$4.71 |
$118 |
D/D |
(25) |
109,920 |
|
10% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2025-06-20 |
4 |
S |
$5.13 |
$21,084 |
D/D |
(4,110) |
109,945 |
|
16% |
|
| Paterson Dan |
President and CEO |
• • – |
2025-06-20 |
4 |
S |
$5.13 |
$91,355 |
D/D |
(17,808) |
443,839 |
|
16% |
|
| Paterson Dan |
President and CEO |
• • – |
2025-06-16 |
4 |
S |
$5.65 |
$1,893 |
D/D |
(335) |
461,647 |
|
26% |
|
| Gagnon Robert E. |
Director |
– • – |
2025-06-16 |
4 |
S |
$5.65 |
$1,605 |
D/D |
(284) |
42,242 |
|
26% |
|
| Stuglik Brian M |
Director |
– • – |
2025-06-16 |
4 |
S |
$5.65 |
$3,356 |
D/D |
(594) |
102,326 |
|
26% |
|
| Stuglik Brian M |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
102,920 |
|
- |
|
| Rowinsky Eric K |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
16,666 |
|
- |
|
| Kapur Anil |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
16,666 |
|
- |
|
| Kauffman Michael |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
17,216 |
|
- |
|
| Johnson John H |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
16,666 |
|
- |
|
| Bunn Paul A. |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
16,666 |
|
- |
|
| Tollefson Karin Anna |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
16,666 |
|
- |
|
| Gagnon Robert E. |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
42,526 |
|
- |
|
| Robertson Michelle |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
16,666 |
|
- |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2025-05-20 |
4 |
S |
$8.13 |
$90,593 |
D/D |
(11,143) |
114,055 |
|
48% |
|
| Paterson Dan |
President and CEO |
• • – |
2025-05-20 |
4 |
S |
$8.13 |
$477,044 |
D/D |
(58,677) |
461,982 |
|
48% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2025-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
38,850 |
125,198 |
|
- |
|
| Paterson Dan |
President and CEO |
• • – |
2025-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
520,659 |
|
- |
|
| Paterson Dan |
President and CEO |
• • – |
2025-05-05 |
4 |
S |
$7.30 |
$5,986 |
D/D |
(820) |
345,659 |
|
41% |
|
| Ros Matthew |
Chief Operating Officer |
• – – |
2025-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2025-03-24 |
4 |
S |
$7.04 |
$183 |
D/D |
(26) |
86,348 |
|
40% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2025-03-20 |
4 |
S |
$6.89 |
$448 |
D/D |
(65) |
86,374 |
|
39% |
|
| Gagnon Robert E. |
Director |
– • – |
2025-03-17 |
4 |
S |
$6.95 |
$1,974 |
D/D |
(284) |
34,193 |
|
42% |
|
| Paterson Dan |
President and CEO |
• • – |
2025-03-17 |
4 |
S |
$6.95 |
$1,696 |
D/D |
(244) |
346,479 |
|
42% |
|
196 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.24%) 
